Welcome to our dedicated page for Genprex news (Ticker: GNPX), a resource for investors and traders seeking the latest updates and insights on Genprex stock.
Genprex, Inc. develops clinical-stage gene therapies for cancer and diabetes, with recurring updates centered on Reqorsa® Gene Therapy (quaratusugene ozeplasmid) and its diabetes gene therapy candidate Pdx1/MafA, also referred to as GPX-002. Reqorsa uses a non-viral, lipid-based nanoparticle delivery approach for a TUSC2 gene-expressing plasmid and is being developed with approved cancer drugs for non-small cell lung cancer and small cell lung cancer.
Company news commonly covers patent grants and licensed intellectual property for Reqorsa combinations with PD-1 and PD-L1 antibodies, biomarker research involving TROP2 and PTEN, preclinical and clinical data presentations, sponsored research with UT MD Anderson, oncology trial references such as Acclaim-1 and Acclaim-3, diabetes preclinical research, industry conference participation and Nasdaq compliance updates.
Genprex (NASDAQ: GNPX) announced its participation in the 2024 BIO Europe Conference, scheduled for Nov. 4-6, 2024 in Stockholm, Sweden, with virtual sessions on Nov. 12-13, 2024. Senior VP of Intellectual Property and Licensing Thomas Gallagher will attend in person, while CEO Ryan Confer and CMO Mark Berger will participate virtually.
The clinical-stage gene therapy company, focused on developing therapies for cancer and diabetes, will conduct one-on-one meetings with industry and investor groups during the conference. Interested parties can request meetings through the conference portal or contact Investor Relations directly.
Genprex announced positive preclinical data for its lead drug candidate, Reqorsa® Gene Therapy, presented at the 2024 EORTC-NCI-AACR Symposium. The research showed promising results in treating Ras inhibitor resistant lung cancer, mesothelioma, and glioblastoma. The company filed two provisional patent applications based on the data for treating mesothelioma and glioblastoma. The presentations, delivered by research collaborators from prestigious institutions including MD Anderson Cancer Center, NYU Langone Health, and UT Health Science Center, focused on TUSC2 gene therapy's potential in treating these challenging cancers.
Genprex (NASDAQ: GNPX) has entered into a Sponsored Research Agreement with the University of Michigan Rogel Cancer Center to study TUSC2 combined with ALK-inhibitors in ALK-EML4 positive lung cancer. The company also announced a collaboration with ALK Positive, a non-profit patient research organization. Preclinical data presented at AACR 2024 showed REQORSA induced apoptosis in alectinib resistant EML4-ALK positive NSCLC cell lines. The research targets ALK+ lung cancer, found in approximately 5% of NSCLCs, where about 82% have decreased TUSC2 tumor suppressor protein. While current ALK-targeted therapies show initial benefits, resistance develops over time, with a 5-year survival rate of 40.9%.
Genprex (NASDAQ: GNPX) has announced progress in its Acclaim-3 clinical trial for Reqorsa® Gene Therapy combined with Tecentriq® in extensive stage small cell lung cancer (ES-SCLC). The company has completed the 0.09 mg/kg dose group and received approval to advance to the highest dose group of 0.12 mg/kg. Key points include:
- No dose limiting toxicities observed
- A partial remission noted in the first patient treated
- The combination therapy has received FDA Fast Track Designation and Orphan Drug Designation
- Phase 1 dose escalation is expected to complete in the second half of 2024
- Phase 2 expansion will enroll 50 patients at 10-15 U.S. sites
Preclinical data showed the combination therapy provided better tumor control than either agent alone in SCLC mouse models.
Genprex announced that its research collaborators will present positive preclinical data on Reqorsa® Gene Therapy at the 2024 EORTC-NCI-AACR Symposium. The presentations will cover Reqorsa's potential in treating Ras inhibitor resistant lung cancer, mesothelioma, and glioblastoma. Key findings include:
1. Reqorsa overcomes acquired resistance to Lumakras® in KRASG12C mutant NSCLC.
2. Reqorsa demonstrates potent tumor suppressive activity in mesothelioma cells.
3. Reqorsa induces apoptosis and shows promising efficacy in glioblastoma cells.
Genprex has filed two provisional patent applications based on the mesothelioma and glioblastoma data. The company views these results as validation of Reqorsa's potential in treating difficult cancers and possible expansion of its clinical development pipeline.
Genprex announced that its research collaborators at Meharry Medical College will present positive preclinical data on Reqorsa® Gene Therapy at the 39th Annual Society for Immunotherapy of Cancer Meeting in Houston, Texas, from November 6-10, 2024. The poster presentation will focus on Reqorsa's ability to modulate in vivo immune responses against cancers.
The study evaluates TUSC2's role in modulating immune responses in cancer. TUSC2 is the tumor suppressor gene used in REQORSA, which consists of a TUSC2 gene expressing plasmid encapsulated in non-viral lipid-based nanoparticles. REQORSA is designed to deliver the functioning TUSC2 gene to cancer cells while minimizing uptake by normal tissue.
Ryan Confer, President and CEO of Genprex, expressed enthusiasm about the growing preclinical evidence supporting REQORSA's potential in treating various cancers and the opportunity to present these findings at the prestigious cancer meeting.
Genprex, Inc. (NASDAQ: GNPX), a clinical-stage gene therapy company, has been featured in CEO/CFO Magazine. The article highlights the company's innovative gene therapies for cancer and diabetes. Ryan Confer, Genprex's President, CEO, and CFO, discussed:
- The company's gene therapy approaches in oncology and diabetes
- Recent updates to the Acclaim clinical trials in lung cancer
- New use of biomarker testing for the oncology program
- The popularity of GLP-1 agonists in diabetes treatment
- Potential partnerships and collaborations in gene therapy
- Plans to spin out the diabetes program into a wholly-owned subsidiary
Confer emphasized the importance of finding the right funding, partners, and collaborators to accelerate bringing innovative drugs to patients and creating value for stakeholders.
Genprex (NASDAQ: GNPX) has formed a Mesothelioma Clinical Advisory Board to support its preclinical mesothelioma oncology program. The board consists of four renowned researchers specializing in mesothelioma treatment. This initiative aims to advance Genprex's Reqorsa® Gene Therapy, which uses the TUSC2 tumor suppressor gene. TUSC2 expression is downregulated in 84% of mesotheliomas, and Genprex's collaborators will present additional positive preclinical data next month at the 2024 EORTC-NCI-AACR Symposium.
Reqorsa® uses Genprex's Oncoprex® Delivery System to target cancer cells while minimizing uptake by normal tissue. Mesothelioma affects approximately 3,000 new cases annually in the U.S., with a life expectancy of 18 months for pleural mesothelioma and a 3-year survival rate of 23% with treatment.
Genprex (NASDAQ: GNPX) announced that its research collaborators will present positive preclinical data on Reqorsa® Gene Therapy at the 2024 EORTC-NCI-AACR Symposium. The presentations will focus on Reqorsa as a potential treatment for Ras inhibitor resistant lung cancer, mesothelioma, and glioblastoma. Three posters will be presented, showcasing studies conducted with academic partners.
Genprex has filed two provisional patent applications based on the data, one for treating mesothelioma and another for glioblastoma. The company is co-owner of these applications with the respective institutions. Reqorsa uses the TUSC2 tumor suppressor gene encapsulated in non-viral lipid-based nanoparticles, designed to target cancer cells while minimizing uptake by normal tissue.
Genprex (NASDAQ: GNPX) has announced plans to create a new subsidiary focused on developing GPX-002, a gene therapy for Type 1 and Type 2 diabetes. This move aims to separate the diabetes program from Genprex's oncology portfolio, potentially attracting more investors and expediting clinical development. The spin-out is expected to occur by the end of 2024, subject to financing and board approval.
The new company would become a pure-play diabetes-focused biopharmaceutical entity, while Genprex would concentrate on oncology. GPX-002, licensed from the University of Pittsburgh, uses an AAV vector containing Pdx1 and MafA genes administered directly into the pancreatic duct. This approach could potentially replace daily blood glucose monitoring and insulin therapy, as well as GLP-1 treatments in Type 2 diabetes.